Aurora Cannabis Inc. Q3 2026 Earnings Recap

ACB Q3 2026 February 4, 2026

Get alerts when ACB reports next quarter

Aurora Cannabis Inc. delivered a strong Q3 2026 performance with a 7% increase in net revenue, driven primarily by robust international medical cannabis growth. The company reported positive free cash flow and improved margins while focusing on strategic market exits to enhance profitability.

Earnings Per Share Miss

$0.09 vs $0.10 est.

-7.4% surprise

Revenue Beat

68589890 vs 67263590 est.

+2.0% surprise

Market Reaction

1-Day -11.73%

5-Day -8.27%

30-Day -6.67%

See ACB alongside your other holdings

Add to your portfolio — free

Key Takeaways

Net revenue increased by 7%, with a 12% rise in global medical cannabis sales, surpassing expectations.
Adjusted gross margin improved to 62%, supported by a strong international performance with medical cannabis margins at 69%.
Achieved positive adjusted EBITDA of $18.5 million and free cash flow of $15.5 million, maintaining a solid balance sheet with over $150 million in cash.
Initiating exits from lower-margin Canadian consumer cannabis markets to concentrate resources on higher-margin global medical cannabis growth.
Announced a new at-the-market equity program to raise up to $100 million for strategic investments including cultivation capacity enhancements.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ACB on AllInvestView.